CONCORDBIO - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.0
| Stock Code | CONCORDBIO | Market Cap | 12,052 Cr. | Current Price | 1,152 ₹ | High / Low | 2,150 ₹ |
| Stock P/E | 37.9 | Book Value | 174 ₹ | Dividend Yield | 0.92 % | ROCE | 28.4 % |
| ROE | 21.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,131 ₹ | DMA 200 | 1,326 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.36 % | PAT Qtr | 70.2 Cr. | PAT Prev Qtr | 62.9 Cr. |
| RSI | 49.7 | MACD | 9.61 | Volume | 45,873 | Avg Vol 1Wk | 92,557 |
| Low price | 987 ₹ | High price | 2,150 ₹ | PEG Ratio | 1.41 | Debt to equity | 0.00 |
| 52w Index | 14.2 % | Qtr Profit Var | -5.20 % | EPS | 30.1 ₹ | Industry PE | 30.5 |
📊 Financial Overview: Concord Biotech (CONCORDBIO) shows solid fundamentals with ROE at 21.4% and ROCE at 28.4%, reflecting efficient capital deployment. Debt-to-equity is 0.00, indicating a debt-free balance sheet. Dividend yield is modest at 0.92%. Quarterly PAT rose from ₹62.9 Cr. to ₹70.2 Cr., though profit variation is reported at -5.20%, suggesting margin pressures despite growth.
💹 Valuation Indicators: Current P/E of 37.9 is above the industry average of 30.5, indicating premium valuation. P/B ratio is ~6.6 (1152/174), which is moderate compared to peers. PEG ratio of 1.41 suggests reasonable growth relative to valuation. Intrinsic value appears slightly lower than current price, implying cautious accumulation.
🏢 Business Model & Advantage: Concord Biotech operates in the biopharmaceutical space, specializing in fermentation-based APIs and immunosuppressants. Its competitive advantage lies in niche expertise, regulatory approvals, and global client base. The company benefits from high entry barriers and strong demand in healthcare markets.
📈 Entry Zone: A favorable entry zone lies between ₹1,050–1,100, closer to support levels and below intrinsic value. Current price (₹1,152) is slightly above this zone, so staggered accumulation is advisable.
🔒 Long-Term Holding Guidance: Concord Biotech is a promising long-term play due to its strong industry positioning, debt-free structure, and consistent profitability. While valuations are stretched, its niche biopharma focus supports sustainable growth. Long-term investors can hold with confidence, monitoring earnings and industry trends.
Positive
- 🌟 Strong ROCE (28.4%) and ROE (21.4%)
- 🌟 Debt-free balance sheet (0.00 debt-to-equity)
- 🌟 Growing PAT (₹70.2 Cr. vs ₹62.9 Cr.)
- 🌟 Niche expertise in biopharmaceutical APIs
Limitation
- ⚠️ Elevated P/E (37.9) vs industry average (30.5)
- ⚠️ Profit variation (-5.20%) despite PAT growth
- ⚠️ Dividend yield relatively low (0.92%)
Company Negative News
- 📉 Reported quarterly profit variation of -5.20%
- 📉 DII holdings decreased (-0.36%)
Company Positive News
- 📈 FII holdings increased (+0.21%)
- 📈 PAT growth from ₹62.9 Cr. to ₹70.2 Cr.
Industry
- 🏦 Industry P/E at 30.5 indicates sector-wide premium valuations
- 🏦 Biopharma sector growth supports Concord Biotech’s long-term prospects
Conclusion
✅ Concord Biotech is financially strong with a debt-free balance sheet and solid returns. Current valuations are slightly stretched, making ₹1,050–1,100 a better entry zone. Long-term investors can hold confidently, leveraging its niche biopharma expertise and industry tailwinds.
Would you like me to also prepare a growth outlook analysis, focusing on its pipeline and global expansion opportunities?